Ludovic Fenaux, Senior VP at Vertex, expressed pride in the availability of ALYFTREK®, emphasizing its role in enhancing treatment options for CF patients and highlighting the drug's efficacy shown in pivotal studies, which suggest better patient outcomes compared to existing therapies like KAFTRIO® (ivacaftor/tezacaftor/elexacaftor). The agreement acknowledges ALYFTREK®'s value to CF patients and their families, and to society overall. With European regulatory approval secured, Vertex plans to extend access to patients in other countries, starting with Ireland, Denmark, and Germany, while continuing discussions with other EU reimbursement bodies to expedite access for all eligible patients. Cystic fibrosis is a serious genetic condition affecting over 109,000 people globally, particularly impacting the lungs and leading to severe complications.